ENTPD1 and neoplasm: B7-H3 inhibition in mTORC1-hyperactive cells suppresses tumor growth by increasing IFN-γ responses and major histocompatibility complex II (MHC-II) expression in the tumor cells and enhancing CD38+CD39+CD4+ T lymphocyte-mediated antitumor immunity.